Slide 1: Q2 2023 Results
July 28, 2023 Q2 2023 Results Stephan Tanda, President & CEO and Bob Kuhn, Executive Vice President and CFO APTAR COMMUNICATIONS GUIDEBOOK
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q2 2023 Financial Highlights
Q2 2023 Financial Highlights Highlights: +6% Reported Sales Growth +4% Core Sales Growth* • Achieved core sales growth and delivered double-digit adjusted EPS growth due to the continued strong demand for our pharma proprietary dosing and dispensing systems, as well as our fragrance dispensing techn
Slide 4: A Sustainable, Socially Responsible Company
A Sustainable, Socially Responsible Company Most Recent Recognitions 2022 Corporate Sustainability Report Recent Sustainable Product Innovations Barron’s logo used with permission. ©2023 Dow Jones & Company, Inc. https://www.aptar.com/esg/reporting-center/ 4
Slide 5: Recent Innovations and Solutions on the Market
Recent Innovations and Solutions on the Market Aptar Pharma Aptar Beauty Aptar Closures • Proprietary spray pump with electronic • Fully recyclable, mono-material pump is the • Snap top closure with flow control valve is counter and lockout device is the drug dispensing solution for J&J’s Neutrogena
Slide 6: Shareholder Value
Shareholder Value Highlights • In the first half of 2023, we returned approximately $79 million to shareholders through dividends and share repurchases • On July 13 we announced an almost 8% increase in our quarterly dividend, underscoring our Board of Directors’ confidence in our strong performance
Slide 7: Second Quarter 2023 Reported Results
Second Quarter 2023 Reported Results Reported Q2 Sales Reported Q Q2Sales EPS Q2 Highlights Re(in millions $) $1.40 $1.24 $1,000 $845 6% $896 $1.20 31% • Aptar Pharma’s performance in the quarter $800 $0.95 $1.00 was driven by strong core sales for $600 $0.80 proprietary drug delivery systems used f
Slide 8: Second Quarter 2023 Adj. EPS and Adj. EBITDA
Second Quarter 2023 Adj. EPS and Adj. EBITDA Reported Adjusted Q Q2Sales EPS* Adjusted ReportedQ2 Q2EBITDA Sales $1.40 (in millions $) $1.23 $200 $181 $1.20 26% $160 13% $0.98 $1.00 $150 $0.80 $0.60 $100 $0.40 $0.20 $50 $- Q2 2022 Q2 2023 $- Q2 2022 Q2 2023 29% 25% Q2 2022 Q2 2023 Effective Tax Effe
Slide 9: Six Months Year-to-Date 2023 Reported Results
Six Months Year-to-Date 2023 Reported Results ReportedYTD Reported YTDSales Sales Reported YTD EPS YTD Highlights (in millions $) $2,000 $1,756 $2.50 $1,689 4% 10% $2.07 $2.00 $1.88 • Aptar had an exceptionally strong first half $1,500 $1.50 of the year due to the tremendous growth $1,000 of our pha
Slide 10: Six Months Year-to-Date 2023 Adj. EPS and Adj. EBITDA
Six Months Year-to-Date 2023 Adj. EPS and Adj. EBITDA Adjusted YTD Adjusted EPS* YTD EPS* Adjusted YTD EBITDA (in millions $) $2.50 $2.18 $1.91 14% $400 $2.00 6% $335 $350 $316 $300 $1.50 $250 $1.00 $200 $150 $0.50 $100 $- $50 YTD 2022 YTD 2023 $- YTD 2022 YTD 2023 28% 25% YTD 2022 YTD 2023 Effectiv
Slide 11: Outlook
Outlook Outlook Highlights Earnings Per Share • Demand for our pharma proprietary $1.40 $1.23 – $1.31 25-27% drug delivery systems and fragrance $1.20 dispensing technologies is expected to $1.01 $1.00 Q3 expected continue into the third quarter $0.81 $0.80 tax rate range • Team has done an excellen
Slide 12: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 12